Company / Cash & Equivalents
Lucid Diagnostics Inc. Cash & Equivalents History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$22.4M
FY2024
5-year range
$18.9M / $22.5M
FY2022-FY2024
Trend
+18.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$22M in FY2024.
Remained stable around $22M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, cash & equivalents increased 18.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -4.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $22.4M | +18.3% |
| FY2023 | $18.9M | -15.9% |
| FY2022 | $22.5M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 24, 2026